Vanguard Capital Management
OCUL icon

Vanguard Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Vanguard Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.7M Buy
8,832,595
+113,556
+1% +$1.03M ﹤0.01% 1627
2026
Q1 		$73.9M Buy
+8,719,039
New +$83.1M ﹤0.01% 1636

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management's OCUL Position: Q2 2026 in Review

Vanguard Capital Management increased its Ocular Therapeutix (OCUL) stake by 1.3% in Q2 2026, buying an estimated $1.03M and bringing the position to 8,832,595 shares worth $86.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1627.

Vanguard Capital Management first reported a position in OCUL in Q1 2026 and has held it in 2 quarters since. 260 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Vanguard Capital Management held 8,832,595 shares of Ocular Therapeutix worth $86.7M as of Q2 2026.
  • Vanguard Capital Management bought 113,556 Ocular Therapeutix shares in Q2 2026, an estimated $1.03M.
  • Ocular Therapeutix made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1627 holding.
  • Vanguard Capital Management first reported a position in Ocular Therapeutix in Q1 2026 and has held it in 2 quarters since.
  • 260 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.